ResearcherVeterans Health AdministrationActive in the last 2 years
Snigdha Banerjee
Matched on ORCID iD 0000-0003-1431-0774; OpenAlex author ID A5031790946. Sources: OpenAlex.
Their work
- Papers
- 9 (first author 0, last author 4)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 15
2016: 2 papers · 2017: none · 2018: 1 paper · 2019: 3 papers · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper
Papers 9
- Targeted nanoencapsulation of tunicamycin reduces toxicity while improving its therapeutic effectiveness in pancreatic cancer cells. Last author DOI 10.1016/j.omton.2025.201047↗
- pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells … Co-author DOI 10.1371/journal.pone.0297749↗
- pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer. Co-author DOI 10.1021/acs.molpharmaceut.0c00499↗
- Microenvironment-sensing, nanocarrier-mediated delivery of combination chemotherapy for pancreatic cancer. Co-author DOI 10.1007/s12079-019-00514-w↗
- CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1535-7163.mct-18-0899↗
- Cyr61/CCN1 targets for chemosensitization in pancreatic cancer. Co-author DOI 10.18632/oncotarget.26986↗
- The MAZ transcription factor is a downstream target of the oncoprotein Cyr61/CCN1 and promotes pancreatic cancer cell invasion via CRAF-ERK signaling. Last author DOI 10.1074/jbc.ra117.000333↗
- Human pancreatic cancer progression: an anarchy among CCN-siblings. Last author DOI 10.1007/s12079-016-0343-9↗
- The miRacle in Pancreatic Cancer by miRNAs: Tiny Angels or Devils in Disease Progression. Co-author DOI 10.3390/ijms17060809↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Sushanta K. Banerjee · 9 shared papers, 2016–2025 · strength 1.05
- Paper Targeted nanoencapsulation of tunicamycin reduces toxicity while improving its therapeutic effectiveness in pancreatic … DOI 10.1016/j.omton.2025.201047↗
- Paper pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant… DOI 10.1371/journal.pone.0297749↗
- Paper Cyr61/CCN1 targets for chemosensitization in pancreatic cancer. DOI 10.18632/oncotarget.26986↗
- Arnab Ghosh · 7 shared papers, 2016–2024 · strength 0.72
- Paper pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant… DOI 10.1371/journal.pone.0297749↗
- Paper Cyr61/CCN1 targets for chemosensitization in pancreatic cancer. DOI 10.18632/oncotarget.26986↗
- Paper Microenvironment-sensing, nanocarrier-mediated delivery of combination chemotherapy for pancreatic cancer. DOI 10.1007/s12079-019-00514-w↗
- Mohiuddin Quadir · 4 shared papers, 2019–2025 · strength 0.63
- Paper Targeted nanoencapsulation of tunicamycin reduces toxicity while improving its therapeutic effectiveness in pancreatic … DOI 10.1016/j.omton.2025.201047↗
- Paper pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant… DOI 10.1371/journal.pone.0297749↗
- Paper pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth i… DOI 10.1021/acs.molpharmaceut.0c00499↗
- Debasmita Dutta · 3 shared papers, 2021–2025 · strength 0.54
- Paper Targeted nanoencapsulation of tunicamycin reduces toxicity while improving its therapeutic effectiveness in pancreatic … DOI 10.1016/j.omton.2025.201047↗
- Paper pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant… DOI 10.1371/journal.pone.0297749↗
- Paper pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth i… DOI 10.1021/acs.molpharmaceut.0c00499↗
- Priyanka Ray · 3 shared papers, 2019–2024 · strength 0.41
- Paper pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant… DOI 10.1371/journal.pone.0297749↗
- Paper pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth i… DOI 10.1021/acs.molpharmaceut.0c00499↗
- Paper Microenvironment-sensing, nanocarrier-mediated delivery of combination chemotherapy for pancreatic cancer. DOI 10.1007/s12079-019-00514-w↗
- Sanku Mallik · 3 shared papers, 2019–2021 · strength 0.29
- Paper pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth i… DOI 10.1021/acs.molpharmaceut.0c00499↗
- Paper Microenvironment-sensing, nanocarrier-mediated delivery of combination chemotherapy for pancreatic cancer. DOI 10.1007/s12079-019-00514-w↗
- Paper CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma. DOI 10.1158/1535-7163.mct-18-0899↗
- Daniel J. Mettman · 1 shared paper, 2025 · strength 0.22
- Stefan H. Bossmann · 1 shared paper, 2025 · strength 0.22
- Gargi Maity · 3 shared papers, 2016–2019 · strength 0.21
- Paper CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma. DOI 10.1158/1535-7163.mct-18-0899↗
- Paper The MAZ transcription factor is a downstream target of the oncoprotein Cyr61/CCN1 and promotes pancreatic cancer cell i… DOI 10.1074/jbc.ra117.000333↗
- Paper Human pancreatic cancer progression: an anarchy among CCN-siblings. DOI 10.1007/s12079-016-0343-9↗
- Gauthami Nair · 2 shared papers, 2019–2021 · strength 0.21
- Paper pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth i… DOI 10.1021/acs.molpharmaceut.0c00499↗
- Paper Microenvironment-sensing, nanocarrier-mediated delivery of combination chemotherapy for pancreatic cancer. DOI 10.1007/s12079-019-00514-w↗
- Katie M. Reindl · 2 shared papers, 2019–2021 · strength 0.21
- Paper pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth i… DOI 10.1021/acs.molpharmaceut.0c00499↗
- Paper Microenvironment-sensing, nanocarrier-mediated delivery of combination chemotherapy for pancreatic cancer. DOI 10.1007/s12079-019-00514-w↗
- Daniel D. Von Hoff · 2 shared papers, 2016–2019 · strength 0.14
- Megan Orr · 1 shared paper, 2021 · strength 0.11
- Amlan Kumar Das · 1 shared paper, 2019 · strength 0.08
- Zuhair Hawa · 1 shared paper, 2016 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.